Alcon Inc Stock Price, News & Analysis

Summary not available.

Summary not available.

Summary not available.

Alcon (SIX/NYSE: ALC) will host its first in-person Annual General Meeting (AGM) since becoming independent in April 2019, on May 5, 2023. Key agenda items include approving annual financial statements for 2022 and the Board's proposal for a CHF 0.21 cash dividend per share, expected to be payable around May 12, 2023. The Board also proposes amendments to the Articles of Incorporation to align with recent Swiss corporate law reforms. Notably, no future virtual AGMs will be approved. Shareholders will vote on compensation for Board and Executive Committee members, among other items.

Alcon has received the Silver Anthem Award for its innovative compliance training program, The Lens, recognized as the Best Special Workforce Initiative: Health in the 2nd Annual Anthem Awards. Developed by Alcon’s Legal and Compliance team in collaboration with Labyrinth Training, The Lens features five interactive episodes addressing various compliance topics. Launched globally in 17 languages, it achieved an impressive completion rate of 81% among associates within 60 days. This recognition follows several other accolades received by Alcon, including awards for leadership and corporate social responsibility.

Alcon (NYSE: ALC), a leader in eye care, will host its 2023 Capital Markets Day on March 30, 2023, starting at 8:00 a.m. CT. The event will feature key updates and strategic insights, accessible via a live webcast at investor.alcon.com.

With over 75 years of history, Alcon offers a vast portfolio of surgical and vision care products, improving the lives of over 260 million people annually across 140 countries. Their commitment to enhancing quality of life through innovative eye care solutions is pivotal in addressing conditions like cataracts and glaucoma.

Alcon has launched TOTAL30 for Astigmatism, the first reusable Water Gradient toric lens, now available to U.S. Eye Care Professionals. This lens enhances comfort and mimics the ocular surface structure, addressing the needs of the growing astigmatic market. Alcon also showcases its expanded toric lens portfolio, including DAILIES TOTAL1 and PRECISION1 for Astigmatism, at the SECO International meeting in Atlanta. Clinical data presentations will highlight the efficacy of its vision care and dry eye products. Alcon's ongoing commitment to innovation aims to improve patient care and comfort in the ocular health sector.

Alcon reported fourth quarter 2022 sales of $2.2 billion, up 1% year-over-year, or 7% on a constant currency basis. For full-year 2022, sales reached $8.7 billion, a 5% increase, with diluted EPS at $0.68, down 11%, but up 37% in constant currency. Key segments included Surgical sales of $1.3 billion, a 1% increase, and Vision Care sales of $0.9 billion, up 1%. The company expects mid-to-high single-digit sales growth and high teens earnings growth for 2023, with a proposed dividend of CHF 0.21 per share subject to shareholder approval.

Alcon, a leader in eye care, has reached a settlement with J&J Surgical Vision, Inc. to resolve ongoing legal disputes over femtosecond laser assisted cataract surgery devices, particularly the LenSx® device. As part of this agreement, Alcon will pay USD 199 million to J&J for cross-licenses of certain intellectual property and to settle various worldwide intellectual property disputes. This settlement aims to mitigate legal uncertainties and enhance Alcon's operational focus, allowing it to continue its mission to improve global eye care.